Neurocrine Biosciences (NBIX) Cash & Equivalents (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Cash & Equivalents of $332.4 million for Q2 2026, up 25.91% year-over-year from $264.0 million in Q2 2025, and up 24.73% on a QoQ basis from $266.5 million in Q1 2026.
Neurocrine Biosciences (NBIX) Cash & Equivalents (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Cash & Equivalents for 17 years, with the latest figure at $332.4 million in Q2 2026.
- Cash & Equivalents for Q2 2026 came in at $332.4 million, up 25.91% year-over-year; the trailing twelve-month figure through Jun 2026 was $332.4 million (up 25.91% YoY), and the FY2025 annual result was $713.0 million, up 206.01% from the prior year.
- Cash & Equivalents rose to $332.4 million in Q2 2026, from $266.5 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $713.0 million in Q4 2025 and troughed at $103.8 million in Q1 2023.
- A 5-year average of $275.6 million and a median of $265.2 million in 2025 frame the typical range for Cash & Equivalents.
- The widest annual swing landed in 2023, when Cash & Equivalents tumbled 61.58%; it then jumped 281.79% in 2024.
- A 5-year view of Cash & Equivalents shows it stood at $270.7 million in 2022, then dropped by 4.29% to $259.1 million in 2023, then decreased by 10.07% to $233.0 million in 2024, then soared by 206.01% to $713.0 million in 2025, then slumped by 53.38% to $332.4 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $332.4 million in Q2 2026, $266.5 million in Q1 2026, and $713.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 332.40 Mn |
| Mar 31, 2026 | 266.50 Mn |
| Dec 31, 2025 | 713.00 Mn |
| Sep 30, 2025 | 340.20 Mn |
| Jun 30, 2025 | 264.00 Mn |
| Mar 31, 2025 | 194.10 Mn |
| Dec 31, 2024 | 233.00 Mn |
| Sep 30, 2024 | 349.10 Mn |
| Jun 30, 2024 | 139.70 Mn |
| Mar 31, 2024 | 396.30 Mn |
| Dec 31, 2023 | 259.10 Mn |
| Sep 30, 2023 | 293.70 Mn |
| Jun 30, 2023 | 160.20 Mn |
| Mar 31, 2023 | 103.80 Mn |
| Dec 31, 2022 | 270.70 Mn |
| Sep 30, 2022 | 212.20 Mn |
| Jun 30, 2022 | 163.30 Mn |
| Mar 31, 2022 | 270.20 Mn |
| Dec 31, 2021 | 344.00 Mn |
| Sep 30, 2021 | 311.10 Mn |